LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice

Journal of Lipid Research

Volumn 47, Issue 3, 2006, Pages 521-529

  Kypreos, Kyriakos E ^a   Zannis, Vassilis I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus mediated gene transfer; Apolipoprotein E; Bolus apolipoprotein E injection; Low density lipoprotein receptor

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE TRANSFER; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRUS PLAQUE;

ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MICE; MODELS, BIOLOGICAL; MUTATION; PROTEIN BINDING; RECEPTORS, LDL; RECOMBINANT PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33644772107     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500322-JLR200     Document Type: Article

References (38)

1. Zannis, V. I., P. W. Just, and J. L. Breslow. 1981. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33: 11-24.
2. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
3. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
4. Havel, R. J., L. Kotite, J. L. Vigne, J. P. Kane, P. Tun, N. Phillips, and G. C. Chen. 1980. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J. Clin. Invest. 66: 1351-1362.
5. Kypreos, K. E., B. Teusink, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J. 15: 1598-1600.
6. Kypreos, K. E., P. Morani, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. Biochemistry. 40: 6027-6035.
7. Kypreos, K. E., K. W. Van Dijk, A. van Der Zee, L. M. Havekes, and V. I. Zannis. 2001. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J. Biol. Chem. 276: 19778-19786.
8. Kypreos, K. E., X. Li, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2003. Molecular mechanisms of type III hyperlipoproteinemia: the contribution of the carboxy-terminal domain of apoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 42: 9841-9853.
9. Huang, Y., X. Q. Liu, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.
10. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA. 91: 4431-4435.
11. Zannis, V. I., A. Chroni, K. E. Kypreos, H. Y. Kan, T. B. Cesar, E. E. Zanni, and D. Kardassis. 2004. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15: 151-166.
12. Gerritsen, G., K. E. Kypreos, A. van Der Zee, B. Teusink, V. I. Zannis, L. M. Havekes, and K. W. Van Dijk. 2003. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain. J. Lipid Res. 44: 408-414.
13. Kypreos, K. E., K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2005. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. J. Biol. Chem. 280: 6276-6284.
14. Innerarity, T. L., and R. W. Mahley. 1978. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 17: 1440-1447.
15. Herz, J., and T. E. Willnow. 1995. Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipidol. 6: 97-103.
16. Wolf, B. B., M. B. Lopes, S. R. VandenBerg, and S. L. Gonias. 1992. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am. J. Pathol. 141: 37-42.
17. Takahashi, S., Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yamamoto. 1992. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA. 89: 9252-9256.
18. Kim, D. H., H. Iijima, K. Goto, J. Sakai, H. Ishii, H. J. Kim, H. Suzuki, H. Kondo, S. Saeki, and T. Yamamoto. 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271: 8373-8380.
19. Li, X., H. Y. Kan, S. Lavrentiadou, M. Krieger, and V. Zannis. 2002. Reconstituted discoidal apoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of apoE suffices for receptor binding. J. Biol. Chem. 277: 21149-21157.
20. Rohlmann, A., M. Gotthardt, R. E. Hammer, and J. Herz. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101: 689-695.
21. Cooper, A. D. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38: 2173-2192.
22. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, and W. S. Sly, editors. McGraw-Hill, New York. 2863-2913.
23. Rubinsztein, D. C., J. C. Cohen, G. M. Berger, D. R. van der Westhuyzen, G. A. Coetzee, and W. Gevers. 1990. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86: 1306-1312.
24. Ji, Z. S., S. Fazio, Y. L. Lee, and R. W. Mahley. 1994. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J. Biol. Chem. 269: 2764-2772.
25. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA. 95: 2509-2514.
26. Fallaux, F. J., O. Kranenburg, S. J. Cramer, A. Houweling, H. Van Ormondt, R. C. Hoeben, and A. J. van der Eb. 1996. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7: 215-222.
27. Li, X., K. Kypreos, E. E. Zanni, and V. Zannis. 2003. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry. 42: 10406-10417.
28. Mahley, R. W., and S. C. Rall, Jr. 2001. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, and W. S. Sly, editors. McGraw-Hill, New York. 2835-2862.
29. Rall, S. C., Jr., K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley. 1982. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc. Natl. Acad. Sci. USA. 79: 4696-4700.
30. Horie, Y., S. Fazio, J. R. Westerlund, K. H. Weisgraber, and S. C. Rall, Jr. 1992. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267: 1962-1968.
31. Havel, R. J., L. Kotite, J. P. Kane, P. Tun, and T. Bersot. 1983. Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J. Clin. Invest. 72: 379-387.
32. Richard, P., M. P. de Zulueta, I. Beucler, J. L. de Gennes, A. Cassaigne, and A. Iron. 1995. Identification of a new apolipoprotein E variant (E2 Arg142→Leu) in type III hyperlipidemia. Atherosclerosis. 112: 19-28.
33. Lohse, P., W. A. Mann, E. A. Stein, and H. B. Brewer, Jr. 1991. Apolipoprotein E-4Philadelphia (Glu13-Lys,Arg145-Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J. Biol. Chem. 266: 10479-10484.
34. Lohse, P., D. J. Rader, and H. B. Brewer, Jr. 1992. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13-Lys, Arg145-Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J. Biol. Chem. 267: 13642-13646.
35. de Villiers, W. J., D. R. van der Westhuyzen, G. A. Coetzee, H. E. Henderson, and A. D. Marais. 1997. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler. Thromb. Vasc. Biol. 17: 865-872.
36. Gregg, R. E., L. A. Zech, E. J. Schaefer, D. Stark, D. Wilson, and H. B. Brewer, Jr. 1986. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78: 815-821.
37. Espirito Santo, S. M., N. M. Pires, L. S. Boesten, G. Gerritsen, N. Bovenschen, K. W. Van Dijk, J. W. Jukema, H. M. Princen, A. Bensadoun, W. P. Li, et al. 2004. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood. 103: 3777-3782.
38. Innerarity, T. L., R. E. Pitas, and R. W. Mahley. 1979. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J. Biol. Chem. 254: 4186-4190.